Published in
Elsevier, Clinical and Translational Radiation Oncology, (8), p. 12-16
DOI: 10.1016/j.ctro.2017.11.003
Links
Tools
PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.
Journal article published in 2018 by
Ben Fulton,
Susan C. Short 
,
Allan James,
Stefan Nowicki,
Catherine A. McBain ,
Sarah Jefferies,
Caroline Kelly,
Jon Stobo ,
Anna Morris,
Aoife Williamson,
Anthony J. Chalmers
,
Allan James,
Stefan Nowicki,
Catherine A. McBain ,
Sarah Jefferies,
Caroline Kelly,
Jon Stobo ,
Anna Morris,
Aoife Williamson,
Anthony J. Chalmers
This paper is made freely available by the publisher.
Full text: Download
Postprint:
archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.